Author: Fenton, Caroline; Lamb, Yvette N.
Title: COVID-19: State of the Vaccination Cord-id: 7d4728ib Document date: 2021_10_15
ID: 7d4728ib
Snippet: The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) pandemic has led to rapid vaccine development and emergency use (EU) rollout. Six vaccines, including two using novel mRNA technology, are EU-listed by the World Health Organisation, and promising published trial data are available for nine more. While efficacy is good, there are various barriers to their global use. Long-term safety and immunogenicity data are
Document: The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) pandemic has led to rapid vaccine development and emergency use (EU) rollout. Six vaccines, including two using novel mRNA technology, are EU-listed by the World Health Organisation, and promising published trial data are available for nine more. While efficacy is good, there are various barriers to their global use. Long-term safety and immunogenicity data are being collected along the way.
Search related documents:
Co phrase search for related documents- ab activity and acute respiratory syndrome coronavirus: 1
- acute respiratory syndrome and ad adenovirus: 1
- acute respiratory syndrome and additional dose: 1, 2, 3, 4, 5
- acute respiratory syndrome and adequate protection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- acute respiratory syndrome and adolescent child: 1, 2, 3, 4, 5
- acute respiratory syndrome and long last immunity: 1
- acute respiratory syndrome and long term protection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
- acute respiratory syndrome and low income: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute respiratory syndrome and low income country: 1, 2, 3, 4, 5, 6
- acute respiratory syndrome coronavirus and ad adenovirus: 1
- acute respiratory syndrome coronavirus and additional dose: 1, 2, 3, 4
- acute respiratory syndrome coronavirus and adequate protection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute respiratory syndrome coronavirus and adolescent child: 1, 2, 3, 4
- acute respiratory syndrome coronavirus and long last immunity: 1
- acute respiratory syndrome coronavirus and long term protection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- acute respiratory syndrome coronavirus and low income: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute respiratory syndrome coronavirus and low income country: 1, 2, 3, 4
- ad adenovirus and ad vector vaccine: 1, 2
Co phrase search for related documents, hyperlinks ordered by date